Hemorrhagic Cystitis (HC) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Hemorrhagic cystitis (HC) is a diffuse inflammatory condition of the urinary system due to an infectious or noninfectious reason resulting in bleeding from the bladder mucosa. The most common cause is a bacterial infection that responds promptly to treatment. However, chronic and recurrent hemorrhagic cystitis often arises from chemotherapy, radiotherapy, or HSCT treatment. HC is manifested in two forms: early-onset HC, which usually appears within 48–72 h following chemotherapy, and late-onset HC, which occurs during the first 2–3 months after HSCT. Early-onset HC has been associated mainly with cyclophosphamide and busulfan administration. These drugs can damage the uroepithelium directly or through their metabolites. Late-onset HC to be associated with virus reactivation in immune-compromised patients. The main treatment recommendations are based on supportive measures such as hyperhydration, forced diuresis, and continuous bladder irrigation. The chronic form of HC defined Grade I-gross hematuria and thrombocytopenia; Grade II - gross hematuria and clots; Grade III- gross hematuria, clots, and urethral obstruction.

 

Hemorrhagic cystitis (HC) varies between 20% to 55% in all chemotherapy or radiotherapy or HSCT-treated patient pools.

 

The competitive landscape of Hemorrhagic Cystitis (HC) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Hemorrhagic Cystitis (HC) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hemorrhagic Cystitis (HC) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Hemorrhagic Cystitis (HC) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          LP-10   Lipella Pharmaceuticals, Inc.      Phase 2

2          Posoleucel (ALVR105)   AlloVir   Phase 3

3          activated recombinant human factor VII  Novo Nordisk A/S            Phase 2

4          Cidofovir           Gilead Sciences            Phase 1

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more